Purpose: To measure the apparent diffusion coefficient (ADC) values in estrogen receptor-positive (ER1) and axillary lymph node-negative (LN-) invasive breast cancer and investigate the correlation of ADC with Oncotype Dx test recurrence scores (ODxRS). Materials and Methods: This was a Health Insurance Portability and Accountability Act (HIPAA)-compliant single-site retrospective study. Patients underwent preoperative 3.0T MRI scans with additional diffusion-weighted imaging sequential scans (b 5 0, 600 and b 5 0, 1000 s/mm 2 ) from January 2011 to 2013. The study population included 31 ER1/LN-invasive breast cancers, which underwent ODxRS genomic testing. ADC 600 and ADC 1000 parametric maps were generated, and ADC values were calculated from a user-drawn region of interest. ODxRS predicts 10-year recurrence risk in individual patients: low (RS <18), intermediate (RS: 18-30), or high (RS >30). All breast lesions, including subgroups of invasive ductal carcinoma (IDC) lesions and mass-only lesions were dichotomized by RS scores, low-risk versus intermediate/high-risk, and statistical analysis was performed using Mann-Whitney's test (statistical significance at P < 0.05) and receiver operating characteristic (ROC) curves. Multivariate analysis was also performed. Results: Invasive breast cancers, when scored as low-risk by ODxRS, had significantly higher ADC values compared with intermediate/high-risk lesions for both ADC 600 (P 5 0.007) and ADC 1000 (P 5 0.008) mean values. This was true both when analyzing only mass-lesions (P 5 0.03 and 0.01) or only IDCs (P 5 0.001 and 0.009). Conclusion: Preliminary findings suggest that lesion ADC values correlate with recurrence risk likelihood stratified using ODxRS. Hence, ADC is a potential surrogate biomarker for tumor aggressiveness. Level of Evidence: 3 Technical Efficacy: Stage 5
mortality and good prognostic factors) need to be identified accurately so that they can be spared unnecessary aggressive treatment. 4 Diffusion-weighted magnetic resonance imaging (DW-MRI) is emerging as a potential clinical adjunct to dynamic contrast-enhanced (DCE) MRI in the evaluation of prognostic factors in breast cancer (mostly by assessing aggressiveness of malignant lesions), and thus DW-MRI may potentially help plan appropriate treatment management. 5, 6 The DW-MRI sequence measures in vivo the mobility of water (Brownian motion) and obtains the apparent diffusion coefficient (ADC), which is the directly proportional quantitative measure to water diffusion. 7 The measured ADC will have contributions from more restricted intracellular diffusion, diffusion in the extracellular space, and even diffusion within the intravascular compartment as long as they occur within-voxel incoherent displacement of spins. 8 High cell proliferation increases cell density, creating more barriers to extracellular water diffusion and thereby reducing ADC in tumors. Accordingly, recent studies have reported ADC as a new breast cancer prognostic factor related to tumor aggressiveness. 9, 10 Oncotype Dx (Genomic Health, Redwood City, CA) is a gene-expression profiling assay that incorporates the mRNA expression of 21 genes (16 cancer-related genes and five reference genes) using reverse transcriptase-polymerase chain reaction, [11] [12] [13] resulting in a quantitative so-called recurrence score (RS). The principal genes that determine the score are those related to proliferation, ER (estrogen receptor), and human epidermal growth factor receptor (HER2). As a result, a tumor with a higher expression of proliferation will result in a higher score and is likely to show an aggressive behavior in contrast to the tumors with a low score. Since 2007, the American Society of Clinical Oncology recommends the clinical use of Oncotype Dx RS (ODxRS) as a decision-making tool to influence the management of patients with lymph node-negative (LN-), estrogen receptor-positive (ER1) breast cancer. 14 The RS identifies patients most likely to benefit from adjuvant chemotherapy based on their 10-year risk of distant relapse and also those with low risk who are best spared unnecessary treatment. 13, 15 Correlating genomic information with image findings is a new field of research, and the overlap between imaging features and genomic characteristics in breast cancer is not well established. The ability to estimate the likelihood of recurrence on the basis of molecular profile and imaging findings could become an important noninvasive tool for stratifying patients according to prognosis, allowing clinicians to make personalized tailored treatment decisions for an individual patient. [16] [17] [18] Our goal was to measure lesion ADC value at 3T and to assess correlation with ODxRS scores.
Materials and Methods

Subjects
This Health Insurance Portability and Accountability Act (HIPAA)-compliant retrospective study was approved by the local Institutional Review Board with a waiver of informed consent. A total of 854 consecutive patients with BI-RADS 4, 5, or 6 lesions were included, who underwent preoperative 3.0T MRI with an additional DW-MRI sequence between January 2011 and January 2013. All these studies are done at one site within our network. Patients who received neoadjuvant chemotherapy prior to MRI (n 5 37) or with suboptimal DW images (artifacts or poor fat suppression) (n 5 29) were excluded and included only ER 1 and LN-lesions. In this study population, there were 73 ER 1 (HER2-negative, PR-positive), axillary LN-tumors. /s. It should be noted that there was a significant difference between the two ADC values (P 5 0.001).The median ODxRS was 15 (range: 2-43). Twenty-one of 31 (68%) lesions had a low RS, 9/31 (29%) had an intermediate RS, and 1/31 (3%) had a high-risk RS.
A statistically significant difference was observed when ODxRS was stratified as low-risk versus intermediate or high-risk for both ADC 600 (P 5 0.007) and ADC 1000 (P 5 0.008) mean values (Table 2) (Figs. (1 and 2) ). Using univariate analysis and stratifying the lesions according to size, no significant difference (P > 0.05) was (Table 3) . Table 4 
The boxplots (Fig. 4) were also subgrouped based on mass lesions or IDCs and show the statistically different values for ADC 600 and ADC 1000 when considering low or intermediate/high-risk ODxRS. All significant findings also showed significance after adjusting for multiple comparisons (Table 5 ). As noted in the Results, although ADC using either b-value was proved to be significant in stratifying the recurrence score groups, there was also a significant difference observed between ADC 600 and ADC 1000 values. There may be some discrepancies or differences in values for the two ADC parameters due to multiple factors, including the effect of pseudoperfusion, the effect of noise on the measurement, and the impact of TE. In the present study, DWI images were obtained as part of the patient's clinical MRI examination with the "optimal TE," option which automatically estimates the shortest TE for the DWI sequence (based on the gradient strength but not on gradient durations) and the delay between diffusion gradient pulses. Note that the TE difference is in the range of 0-6.4 msec between b600 and b1000 scans within a single study, which may cause a minimal effect on the DW signal. However, overall, it seems as though cellularity is a dominant component that allows for both ADC values to The current study shows that, independent of the tumor size for ER1/LN-lesions, a lower ADC value correlates with an increasing ODxRS and consequently an incremental estimate recurrence risk of cancer. This finding could allow for the use of ADC to identify patients who are at low risk for recurrence and provide an alternate prognostic marker in determining patients who are ER1/ LN-, who require adjuvant chemotherapy.
To our knowledge, only a few studies have investigated the correlation between imaging findings (MR and conventional imaging) with ODxRS. Initially, Daye et al 29 evaluated the tumor features on contrast-enhanced breast MRI as a prognostic marker for breast cancer compared to ODxRS. They retrospectively analyzed 61 women diagnosed with ER1/LN-invasive breast cancer and evaluated seven tumor-specific features, including lesion size and shape, margin morphology, enhancement morphology and amount, presence of multifocal disease, and associated nonmass enhancement. Tumor multifocality and lesion size were the most important in predicting the recurrence risk categories, with the best performance in distinguishing the low-from high-risk groups, suggesting that MRI tumor features can predict the RS category as determined by the ODxRS assay. Yepes et al 16 investigated whether mammographic or sonographic features could predict the ODxRS in patients with T 1 or T 2 tumors, hormone receptor-positive, HER2-negative, and LN-breast cancers. Of all the findings, only pleomorphic microcalcifications within a mass on mammograms and posterior acoustic enhancement on ultrasound reached statistical significance on multivariate logistic regression, resulting in association with intermediate or high-risk RS lesions. However, as reported, there was a markedly low interobserver agreement and a wide variability in predicting the RS, based on the imaging characteristics alone (regardless of years of experience as breast imagers), suggesting that There are limitations to our study. First, it was a retrospective study with a small sample size. There were more patients with a low-risk ODxRS and only one patient who had an RS above 30. As a result, this high-risk ODxRS case was combined with the remaining intermediate-risk patients into one group. Although high-risk patients receive additional chemotherapy treatment, among intermediate-risk patients the oncologist generally decides which patients receive chemotherapy based on the individual patient's clinical history, whereas low-risk patients do not receive any additional treatment. Furthermore, it is noted that the ROI drawn for obtaining ADC measurements may not completely reflect the whole tumor characteristics and may disregard other important features because it came from a single representative slice and not full 3D volumetric analyses. Additionally, more detailed analysis of the MRI data could reveal more features of the tumor microenvironment. Finally, the association between ADC values and disease-free survival, or overall survival, could not be evaluated due to limited follow-up of the population.
In the present work, we focused only on the imagingbased ADC measurement, but we advocate, accordingly with other works studying image-based features correlated with ODxRS, that the combination of the multiple parameters, including standard markers, quantitative image-based features, and diffusion imaging may create an integrated customized prognostic tool that can better support clinical decision-making and prognostic assessment for breast cancer treatment.
In summary, ADC is a potential surrogate biomarker for malignant lesion aggressiveness in ER1/LN-invasive breast cancers and may reflect the expectance of recurrence, or an advantage with chemotherapy, based on ODxRS. However, at the moment pathologic and genetic markers remain far more reliable in indicating prognosis and the need for adjuvant treatment compared with imaging biomarkers. Further studies with larger cohorts would be needed to validate these findings prospectively in association with recurrence outcome, based on patient follow-up to confirm our preliminary data. 
